Telmisartan is an angiotensin receptor blockers (ARB) that has a
longer half-life and penetrates the blood-brain barrier
unlike Benicar(Olmesartan) or Valsartan
described in articles, letters and emails by the Marshall's (marshallprotocol.com).
Telmisartan appears to be distinctly superior for CFIDS.
- Once a day dosage is practical, twice a day preferred
- Reaches the Brain
- As dosage increases, the concentration in the body increases faster than
the dosage (odd - but desirable characteristic)
- Less blood pressure drop than Benicar.
- Since it crosses the brain barrier like
should improve migraines
and may impact cognitive functions.
There are no studies on it's impact on inflammation (but every other one has
been -- with all reducing it).
See: Comparison of ARBs and
Dosing Protocols for more information.
Original 2001 WebSite as PDF for download